Health News
Bone Rx Boosted Breast Cancer Survival
Nearly all postmenopausal women with early-stage HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures.
FDA Approves Prolia for osteoporosis
On September 16, 2011, the U.S. Food and Drug Administration granted approval for denosumab ( Prolia , Amgen Inc.) as a treatment to increase bone mass in patients at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer or adjuvant aromatase inhibitor (AI) therapy for breast cancer. In men with nonmetastatic prostate cancer, denosumab also reduced the incidence of vertebral fracture.